Acorda Therapeutics, Inc.
ACORQ
OTC PK
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -2.22% | -0.79% | -10.43% | -4.18% | -3.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.22% | -0.79% | -10.43% | -4.18% | -3.63% |
| Cost of Revenue | -37.56% | -42.97% | -45.41% | -29.07% | -21.08% |
| Gross Profit | 11.34% | 17.49% | 3.50% | 7.16% | 5.31% |
| SG&A Expenses | -5.93% | -15.38% | -9.27% | -14.89% | -9.28% |
| Depreciation & Amortization | -22.91% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.41% | -11.97% | -22.55% | -22.38% | -17.20% |
| Operating Income | 29.78% | 43.92% | 55.91% | 61.63% | 44.28% |
| Income Before Tax | -920.07% | -739.85% | 75.47% | 77.45% | 69.15% |
| Income Tax Expenses | -244.56% | -240.75% | -108.78% | -100.61% | 1,759.24% |
| Earnings from Continuing Operations | -352.48% | -283.60% | 84.90% | 82.40% | 38.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -352.48% | -283.60% | 84.90% | 82.40% | 38.73% |
| EBIT | 29.78% | 43.92% | 55.91% | 61.63% | 44.28% |
| EBITDA | 126.14% | 196.84% | 198.06% | 142.95% | 92.44% |
| EPS Basic | -236.58% | -135.41% | 90.85% | 90.51% | 62.06% |
| Normalized Basic EPS | 22.11% | 46.86% | 57.56% | 68.47% | 63.85% |
| EPS Diluted | -202.98% | -117.81% | 85.75% | 86.51% | 57.88% |
| Normalized Diluted EPS | 21.63% | 46.63% | 57.94% | 68.75% | 64.08% |
| Average Basic Shares Outstanding | 8.88% | 24.72% | 47.12% | 84.62% | 97.37% |
| Average Diluted Shares Outstanding | -10.20% | 0.31% | 75.98% | 120.84% | 139.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
